ABSTRACT-A quaternary derivative of diltiazem (quat-DTZ) was tested to determine whether diltiazem approaches L-type Ca2+ channels from the outside or inside of the cell membrane. In single ventricular myocytes, both extra and intracellular application of quat-DTZ effectively blocked the L-type Ca2+ chan nel current, whereas D890 was effective only when applied intracellularly. These results strongly suggest that diltiazem binds to the channel from the outside as well as the inside of the membrane in a manner different from that of phenylalkylamines.
Three major types of Ca 2+ antagonists, i.e., 1,4-dihy dropyridines (1,4-DHP), phenylalkylamines and 1,5-ben zothiazepines (1) , are thought to have separate binding sites on the a,-subunit of the L-type Ca2+ channel. Recent ly, the binding sites for 1,4-DHP and phenylalkylamines have been identified on the basis of electrophysiological and biochemical studies (2) . Permanently charged quater nary ammonium ion derivatives of 1,4-DHP and phenyl alkylamines, which are considered not to permeate the cell membrane, have proved to be useful tools for elec trophysiological studies to test whether the binding sites are located on the extracellular or intracellular surface of the cell membrane. The results obtained using quaternary derivatives of phenylalkylamine (D890) (3) and 1,4-DHP (SDZ-270-180) (4) have indicated that the binding site for phenylalkylamines is located on the intracellular surface of the membrane, whereas the 1,4-DHP-binding site lies close to the extracellular surface. However, there is little information on the binding site for 1,5-benzothiazepines. Diltiazem has been reported to be active, like D600, from the inside of the cell membrane (5) . Neverthless, the result did not determine the binding site, because diltiazem is considered to be permeable through the cell membrane.
In the present study, we used a quaternary ammonium ion derivative of diltiazem (quat-DTZ, Fig. IA) to deter mine the side of the cell membrane from which diltiazem has access to the L-type Ca 21 channel. First, we examined the binding properties of quat-DTZ in comparison with those of diltiazem, and then we tested the effects of extra and intracellular application of quat-DTZ on L-type Ca2+ channel currents (ICa(L)) in ventricular myocytes.
Crude T-tubule membranes were prepared from back muscles of male New Zealand white rabbits (1.5 kg) ac cording to the method described by Ikeda et al. (6) (6) .
Ventricular myocytes were isolated from male Hartley guinea pigs (300-400 g) using collagenase (collagenase-S 1, Nitta Gelatin Co., Osaka) according to the methods described by Cavalie et al. (7) . The recordings were made with the whole-cell patch-clamp technique (8) (DAGAN 8900 amplifier with a 100-MI) head stage). The external solution was composed of: 120 mM NaCl, 4 mM KCI, 2 mM CaC12, 2 mM MgC12i 10 mM glucose, 5 mM HEPES and 30 mM tetraethylammonium chloride, (pH 7.4). The tip resistance of the fire-polished glass pipette was 2-4 MQ when filled with pipette solution composed of: 80 mM KCI, 20 mM tetraethylammonium chloride, 40 mM CsOH, 10 mM ethyleneglycol-bis-N,N,N',N'-tetraacetic acid, 10 mM HEPES and 4 mM MgATP (pH 7.4). All the experiments were performed at room temperature.
To determine the onset and recovery of the blocking action of drugs, we used the voltage protocol described by Kass et al. (4) with a small modification. The protocol was based on the idea that the blocking action of diltia zem on the slow inward current in cardiac cells is depend ent on the holding potential (9, 10). The protocol was as follows: Ica(L) was activated by a test pulse to 0 mV for 200 msec at 0.2 Hz. The voltage-dependent Na+ current and T-type current were suppressed by applying a prepulse to -40 mV for 150 msec. The holding potential (Vh) was kept at 90 mV for 5 min until Ica(L) became sta ble, and the external solution including or without the drug was perfused for another 3 min. Then the test pulse was stopped, and Vh was changed to -40 mV. After 10 sec, the test pulse was started again and changes in Ica(L) were estimated for 3 min. The recovery from the block was confirmed by changing Vh from -40 mV to -90 mV. In the case of intracellular drug application, drugs were dissolved in pipette solution and the influences of the drugs on Ica(L) were observed according to the pro tocol described above. Diltiazem and quat-DTZ were supplied by Tanabe Seiyaku Co., Ltd., Saitama. D890 was a gift from Knoll AG, Ludwigshafen, Germany. Bonferroni's multiple t test or Student's t-test was employed to assess the statisti cal significance of differences. Data are represented as the mean±S.E.M. Figure 1B shows These results suggest that quat-DTZ binds to an identi cal site with diltiazem in a competitive manner and exerts a conformational change on the 1,4-DHP binding site similar to that exerted by diltiazem. (n=5, P<0.01 vs. control), respectively. The effective concentration for quat-DTZ was 100 times as high as that for diltiazem (data not shown), the difference being close to that in the K, values for the diltiazem-binding site described above. Intracellularly applied quat-DTZ at 5 x 10-4 M also effectively blocked Ica(L) in a use-depend ent manner to 22.2±6.6% (n=6, P<0.01 vs. control). Extra and intracellular application of potassium iodide up to 10 -3 M had no effect. Figure 2C shows the effects of D890. Extracellular appli cation of D890 at 10-4 M was almost completely ineffec tive (80.6:L6.3%, n=5, not significant vs. control), whereas intracellular application at the same concentra tion suppressed ICa(L) in a use-dependent manner (45.2±5.9%, n=6, P<0.01 vs. extracellular applica tion). Thus we confirmed that D890 acts solely from the in tracellular surface of the cell membrane, as Hescheler et al. reported (3) . These results exclude the possibility of drug action through leakage of the drug from one side of the membrane to the other through the pipette-cell mem brane interface.
Our results demonstrate that quat-DTZ exerts its effects from the outside as well as inside of the cell membrane. Assuming that quat-DTZ does not permeate the cell mem brane, these results suggest two possibilities: one is that the binding site for quat-DTZ is located within the chan nel and thus accessible from both sides, and the other is that quat-DTZ has binding sites with close affinity on both the extracellular and intracellular surfaces of the membrane.
In conclusion, the present results strongly sug gest that diltiazem binds to the channel from the outside as well as inside of the membrane in a manner different from that of phenylalkylamines.
